Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 415

1.

Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.

Chen L, Liang L, Yan X, Liu N, Gong L, Pan S, Lin F, Zhang Q, Zhao H, Zheng F.

Int J Gynecol Cancer. 2013 Feb;23(2):256-63. doi: 10.1097/IGC.0b013e31827ad2b8.

PMID:
23358177
2.

[Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel].

Yan XJ, Liang LZ, Zeng ZY, Shi Z, Fu LW.

Ai Zheng. 2006 Apr;25(4):398-403. Chinese.

PMID:
16613669
3.

[Influence of short hairpin RNA on survivin mRNA expression and chemosensitivity to paclitaxel in ovarian cancer cells].

Yan XJ, Liang LZ, Zeng ZY, Fu LW, Shi Z.

Zhonghua Fu Chan Ke Za Zhi. 2005 Sep;40(9):609-13. Chinese.

PMID:
16202317
4.
5.

[The protein expression of ERCC1 and survivin in epithelial ovarian carcinoma and their clinical significance].

Xie C, Yin RT, Li YL, Kang DY, Xu L, Yang KX.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2011 Jan;42(1):86-9. Chinese.

PMID:
21355309
6.

Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance.

Su L, Wang Y, Xiao M, Lin Y, Yu L.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Oct;110(4):484-91. doi: 10.1016/j.tripleo.2010.04.009.

PMID:
20868995
7.

Expression and role of the inhibitor of apoptosis protein livin in chemotherapy sensitivity of ovarian carcinoma.

Liu X, Wang A, Gao H, Yuan Z, Jiao Y.

Int J Oncol. 2012 Sep;41(3):1021-8. doi: 10.3892/ijo.2012.1540. Epub 2012 Jul 3.

PMID:
22766624
8.

Effect of shRNA targeting survivin on ovarian cancer.

Xing J, Jia CR, Wang Y, Guo J, Cai Y.

J Cancer Res Clin Oncol. 2012 Jul;138(7):1221-9. doi: 10.1007/s00432-012-1196-0. Epub 2012 Mar 18.

PMID:
22426961
9.

[Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].

Li Z, Wang Q, Zhang W, Yang Z, Li L.

Zhonghua Fu Chan Ke Za Zhi. 2015 Nov;50(11):854-60. Chinese.

PMID:
26887775
10.

The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy.

Zhao Y, Zheng HC, Chen S, Gou WF, Xiao LJ, Niu ZF.

Gynecol Oncol. 2013 Sep;130(3):570-8. doi: 10.1016/j.ygyno.2013.06.004. Epub 2013 Jun 10.

PMID:
23764197
11.

Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.

Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A.

J Pathol. 2012 Apr;226(5):746-55. doi: 10.1002/path.3035. Epub 2012 Jan 17. Erratum in: J Pathol. 2014 Feb;232(3):e1.

12.

Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.

Ehlén A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brändstedt J, Uhlén M, Pontén F, Jirström K.

J Transl Med. 2010 Aug 20;8:78. doi: 10.1186/1479-5876-8-78.

13.

Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly.

Hu Q, Li W, Hu X, Hu Q, Shen J, Jin X, Zhou J, Tang G, Chu PK.

Biomaterials. 2012 Sep;33(27):6580-91. doi: 10.1016/j.biomaterials.2012.05.060. Epub 2012 Jun 18.

PMID:
22717365
14.

[Effects of survivin siRNA on growth, apoptosis and chemosensitivity of ovarian cancer cells SKOV3/DDP].

Zhang X, Li N, Wang YH, Huang Y, Xu NZ, Wu LY.

Zhonghua Zhong Liu Za Zhi. 2009 Mar;31(3):174-7. Chinese.

PMID:
19615253
15.

[RNA interference silencing expression of survivin gene and reversing drug resistance of ovarian cancer cell line SKOV3/ADM].

Deng KX, Zhong L, Jiang MX, Wang PL, Chen Y.

Zhonghua Fu Chan Ke Za Zhi. 2005 Dec;40(12):836-9. Chinese.

PMID:
16412331
16.

Expression of livin in gastric cancer and induction of apoptosis in SGC-7901 cells by shRNA-mediated silencing of livin gene.

Wang TS, Ding QQ, Guo RH, Shen H, Sun J, Lu KH, You SH, Ge HM, Shu YQ, Liu P.

Biomed Pharmacother. 2010 May;64(5):333-8. doi: 10.1016/j.biopha.2009.06.002. Epub 2009 Oct 21.

PMID:
19914791
17.

Effects of Livin gene RNA interference on apoptosis of cervical cancer HeLa cells and enhanced sensitivity to cisplatin.

Yu L, Wang Z.

J Huazhong Univ Sci Technolog Med Sci. 2009 Oct;29(5):625-30. doi: 10.1007/s11596-009-0518-1. Epub 2009 Oct 11.

PMID:
19821098
18.

Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.

Sankpal UT, Ingersoll SB, Ahmad S, Holloway RW, Bhat VB, Simecka JW, Daniel L, Kariali E, Vishwanatha JK, Basha R.

Tumour Biol. 2016 Oct;37(10):14259-14269. Epub 2016 Aug 31.

PMID:
27581819
19.

Oxaliplatin-mediated inhibition of survivin increases sensitivity of head and neck squamous cell carcinoma cell lines to paclitaxel.

Khan Z, Khan N, Varma AK, Tiwari RP, Mouhamad S, Prasad GB, Bisen P.

Curr Cancer Drug Targets. 2010 Nov;10(7):660-9.

PMID:
20578991
20.

Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.

Gąsowska-Bodnar A, Bodnar L, Dąbek A, Cichowicz M, Jerzak M, Cierniak S, Kozłowski W, Baranowski W.

Int J Gynecol Cancer. 2014 May;24(4):687-96. doi: 10.1097/IGC.0000000000000108.

PMID:
24662134

Supplemental Content

Support Center